Revance Therapeutics Inc (RVNC)

[10nisman]

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172851256

Foley's last answer around EBITDA / Cash flow guidance is in-line with my early comment. Nobody should have been forecasting any material positive FY 2024 EBITDA, and there was no change in Management guidance other than discontinuing the OPUL business. Maybe certain market participants were baking in much rosier expectations (or some major positive news announcement would be provided today) and are selling, however, today's move doesn't align with the change in the business. I imagine most long investors came away with a positive view of the Company and the long-term expectations especially at current prices.